After-Hours Stock Movers 11/16: (NTAP) (HAIN) (AMGN) Higher; (LEI) (FSLR) (CSCO) Lower (more...)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Today's After-Hours Stock Movers
Lucas Energy (NYSE: LEI) 22.3% LOWER; files prospectus related to 6 million common shares for selling shareholders.
First Solar (NASDAQ: FSLR) 11.3% LOWER; Raises FY16 EPS Guidance by 30c, Lowers FY17; Reports $500M-$700M Impairment Charges
NetApp (NASDAQ: NTAP) 10.6% HIGHER; reported Q2 EPS of $0.60, versus the analyst estimate of $0.54. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.36 billion. GUIDANCE: NetApp sees Q3 2017 EPS of $0.72-$0.77, versus the consensus of $0.65. NetApp sees Q3 2017 revenue of $1.325-1.475 billion, versus the consensus of $1.36 billion.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 10% LOWER; intends to offer and sell, subject to market conditions, up to $65,000,000 of shares of its common stock in an underwritten public offering.
The Hain Celestial Group, Inc. (Nasdaq: HAIN) 8% HIGHER; announced today that the Audit Committee of the Company's Board of Directors has concluded its independent review with external counsel into concessions with respect to certain distributors in the United States. Hain Celestial had previously announced on August 15, 2016 that during the fourth quarter of fiscal year 2016 it had identified concessions that were granted to certain distributors in the United States and that the Audit Committee had retained independent counsel to assist in its independent review of such matter. The review, which was extensive, found no evidence of intentional wrongdoing in connection with the Company's financial statements. Hain Celestial has begun to implement a remediation plan to strengthen its internal controls and organization.
Cisco Systems (NASDAQ: CSCO) 4.3% LOWER; reported Q1 EPS of $0.61, $0.02 better than the analyst estimate of $0.59. Revenue for the quarter came in at $12.4 billion versus the consensus estimate of $12.33 billion. GUIDANCE: Cisco Systems sees Q2 2017 EPS of $0.55-$0.57, versus the consensus of $0.59. Cisco Systems sees FY2017 EPS of $0.55-$0.00.
Planet Fitness, Inc. (NYSE: PLNT) 3.8% LOWER; announced that certain of its existing stockholders (the "Selling Stockholders") intend to offer for sale 15 million shares of its Class A common stock pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission.
SunPower (NASDAQ: SPWR) 3.6% LOWER; down on FSLR warning
Performance Food Group Company (NYSE: PFGC) 2.5% LOWER; announced that certain of its stockholders, including affiliates of The Blackstone Group L.P., intend to offer for sale in an underwritten secondary offering 10,000,000 shares of common stock of the Company.
L Brands (NYSE: LB) 1.4% LOWER; reported Q3 EPS of $0.42, $0.02 better than the analyst estimate of $0.40. Revenue for the quarter came in at $2.58 billion versus the consensus estimate of $2.57 billion. GUIDANCE: L Brands sees Q4 2016 EPS of $1.85-$2.00, versus the consensus of $2.03.
Amgen (Nasdaq: AMGN) 0.6% HIGHER; announced positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE). These data showed the STRIVE study met the primary endpoint, demonstrating statistically significant reductions from baseline in monthly migraine days in patients with episodic migraine treated with either 70 mg or 140 mg erenumab compared with placebo. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Herbalife (NYSE: HLF) volatility low into disclosed that the SEC has requested documents and other information
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesAfter-Hours Movers, S3
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!